BioMérieux Stock Slides After Company Cuts Medium-Term Growth Outlook

Shares in bioMérieux (BIOX.PA) declined on Tuesday after the in vitro diagnostics specialist reduced its medium-term financial targets for 2027 and 2028, signaling a more challenging growth environment ahead.

Guidance Revision

BioMérieux announced it was lowering its multi-year outlook, citing a "shift in the geopolitical and macroeconomic environment since 2024." The company's updated guidance includes:

• An annual organic revenue growth target of 3% to 6% for 2027 and 2028, down from a previously guided compound annual growth rate of approximately 7%.
• Trimmed growth ambitions for its CEBIT (current operating income before non-recurring items) over the same period.

The downward revision of its long-term trajectory was the primary catalyst for the stock's decline, pushing shares down 1.9% to €69.35 in morning trading and toward the stock's 52-week low of €65.60.

Ad

First-Half Performance

The guidance cut overshadowed the company's first-half 2026 results. For the six-month period, bioMérieux reported consolidated sales of €1,965 million, representing nearly flat organic growth of just 0.2%.

The top line was heavily impacted by a 17% organic decline in sales of its BIOFIRE respiratory panels, which the company attributed to a significantly weaker respiratory season compared to the prior year. First-half CEBIT fell 4.9% on an organic basis, while adjusted diluted earnings per share came in at €1.99, a 4% organic decrease.